Atom | Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
This grant has been cancelled by the HHS-NIH11
Please check the funder's website or contact us at support@atomgrants.com for more information.
Other Eligible Applicants include the following:Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Cont...
Start finding grants with Atom for
$0 today
$30 Billed monthly after 7-day trial. Cancel anytime.
Personalized grant emails delivered weekly, right to your inbox.
AI powered search engine with both keyword and semantic search capabilities.
Grant filters to find the perfect funding opportunities.